It has been a big and very busy September for researchers, clinical trials and pharmaceutical companies. Early this month, the Joint ACTRIMS/ECTRIMS Meeting took place in Boston. For more, please check the extensive website of the conference.
- Johns Hopkins Multiple Sclerosis Center receives MS research grant from Progressive Alliance
News-Medical.net – The Johns Hopkins Multiple Sclerosis Center is the recipient of one of 22 research grants offered to investigators in nine countries.
- $31.4 Million in Funding Earmarked For Progressive Multiple Sclerosis Research
Multiple Sclerosis News Today – Progressive Multiple Sclerosis The first round of 22 research grants have been awarded to projects in nine countries by the International Progressive Alliance.
- New MR technique offers new insight into multiple sclerosis
DOTmed.com – A new MR technique called macromolecular proton fraction (MPF) mapping revealed that patients with multiple sclerosis (MS) lose myelin — fatty protective sheath around nerve fibers.
- Study links slowed processing speed with executive deficits in individuals with multiple sclerosis
News-Medical.net – “Does slowed processing speed account for executive deficits in multiple sclerosis?
- Cognitive Training Improves Thalamic Connectivity in MS
Medscape – … A new study shows that cognitive training using a commercially available game led to clinical improvements in patients with multiple sclerosis (MS).
- Kessler Foundation multiple sclerosis researchers find role for working memory in cognitive reserve
Science Codex – Kessler Foundation scientists have shown that working memory may be an underlying mechanism of cognitive reserve in multiple sclerosis
- Diabetes and multiple sclerosis can be reversed say scientists
The Standard Digital News – Diabetes and multiple sclerosis can be reversed say scientists. Updated … could be a cure for conditions like Type 1 diabetes and multiple sclerosis.
- Multiple Sclerosis new drug candidate has promise
Examiner.com – Results from a six-month Phase 2 study of 258 patients suffering from multiple sclerosis show the drug candidate RPC1063 decreased the annualized relapse rate by 53%
- Multiple Sclerosis: Generic Copaxone Demonstrates Equivalent Safety and Efficacy
Medical Research News and Interviews_ MedicalResearch.com – Dr. Cohen: The primary objective of the GATE trial was to compare the efficacy and safety of generic glatiramer acetate.
- Teva, Active Biotech Present Positive Findings for RRMS Experimental Therapy Laquinimod
Multiple Sclerosis News Today – RRMS from Teva During the 30th Congress of the European Committee for Research and Treatment in Multiple Sclerosis (ECTRIMS) last week in Boston presented new follow-up data.
- Biogen Idec’s Study Reviews Positive Results Over Five Years of Tecfidera RRMS Treatment
Multiple Sclerosis News Today – to provide strong and sustained efficacy to patients with relapsing-remitting multiple sclerosis (RRMS), at last week’s ACTRIMS-ECTRIMS summit.
- Multiple Sclerosis Trial for Lisinopril Granted $1.4 Million in New Funding From NCATS
Multiple Sclerosis News Today – The Repurposing a Generic ACE Inhibitor to treat Multiple Sclerosis funding was granted by the National Center for Advancing Translational Sciences.
- Novel MS Therapy from GeNeuro Performed Well in Phase 2a Clinical Trial
Multiple Sclerosis News Today – GNbAC1 MS drug A novel therapeutic from GeNeuro to treat multiple sclerosis showed promising results in a one-year, open-label extension phase.
- Mylan’s Generic Copaxone Injection ANDA Approved for Filling by the FDA
Multiple Sclerosis News Today – However, there are no controlled clinical trials that verified its effects on the reduction of the progression of the disability caused by multiple sclerosis.
Medical treatment news
- Nyack Hospital named MS comprehensive care center
The Journal News | LoHud.com – The National Multiple Sclerosis Society has named Nyack Hospital as one of its centers of comprehensive care for people who have the disease.
- AbbVie, Biogen to file MS drug next year
Medical Marketing and Media – Phase-III results of the AbbVie-Biogen Idec experimental multiple sclerosis shot Zinbryta (daclizumab) indicate the drug bests Biogen’s injectable
- Novartis Presents Data on Multiple Sclerosis Drug Gilenya – Analyst Blog
NASDAQ – Novartis ( NVS ) presented encouraging data on multiple sclerosis (MS) drug, Gilenya, from a follow-up extension study, LONGTERMS.
- EMD Serono Presents New Data on Rebif ® (Interferon beta-1a) and Multiple Sclerosis Pipeline at …
Canada NewsWire (press release) – Data include post-hoc assessments of controlled studies in relapsing MS regarding evolution of gadolinium-enhancing lesions.
- Stretch It Out: Yoga Eases Multiple Sclerosis Symptoms in Pilot Study
Healthline – Stretch It Out: Yoga Eases Multiple Sclerosis Symptoms in Pilot Study. Researchers bent over backwards to help those with MS
- Real-World Analysis of AMPYRA Multiple Sclerosis Drug Presented by Acorda and HealthCore
Multiple Sclerosis News Today – Acorda Therapeutics will present results of a study analyzing AMPYRA (dalfampridine) Extended Release Tablets in multiple sclerosis patients
- Remyelination Therapy Promising in Multiple Sclerosis
Medscape – An experimental monoclonal antibody for multiple sclerosis (MS) that enhances remyelination has shown promise in phase 1 studies.
- Beta-Interferon, Glatiramer Acetate Cost-Effective in MS
Medscape – The study was presented at MS Boston 2014, the 2014 Joint Americas and European Committees for Treatment and Research in Multiple Sclerosis
- Biogen: Still Leading The Multiple Sclerosis Market
Bidness ETC – Multiple sclerosis (MS), despite being a relatively rare disease, has turned into a lucrative market for many pharmaceuticals,
- Market Report, “Global Multiple Sclerosis Drugs Market 2014-2018 “, published
USPRwire (press release) – [USPRwire, Wed Sep 03 2014] Multiple sclerosis is a chronic, inflammatory medical condition that results in demyelination, axonal transection, etc.
© Willeke Van Eeckhoutte and Ireland, Multiple Sclerosis & Me, 2011-2014. Unauthorized use and/or duplication of this material without express and written permission from this blog’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Willeke Van Eeckhoutte and Ireland, Multiple Sclerosis & Me with appropriate and specific direction to the original content.